Abstract
Gene transfer and oncolytic viruses provide new therapeutic approaches for the treatment of hematologic malignancies. However, it is still too early to introduce gene delivery or oncolytic viruses into standard clinical protocol. It is very important to discuss the obstacles that gene transfer and oncolytic virotherapy face for the further clinical application for the treatment of hematologic malignancies, and updating the advances made to overcome them. The major concerns in this review include the approaches of the development of immuno-stimulatory gene transfer mediated-vaccination for leukemia therapy, RNAi-based therapy for leukemia and enhancement of sensitivity of target malignant cells to virotherapy and alteration of host immune response to favor oncolytic viruses. We conclude with a perspective on the future of the gene therapy and virotherapy for the treatment of hematologic malignancies, emphasizing the problems we should solve and the technological requirements for further clinical applications.
Keywords: Gene transfer, vaccination, RNAi, oncolytic viruses, hematologic malignancies.
Current Gene Therapy
Title:Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Volume: 16 Issue: 6
Author(s): Yingzhe Jiang, Bing Xia, Yizhuo Zhang*Wen Xu
Affiliation:
- Tianjin Medical University Cancer Institute and Hospital, 1 Huanhuxi Road, Hexi District, Tianjin 300060,China
Keywords: Gene transfer, vaccination, RNAi, oncolytic viruses, hematologic malignancies.
Abstract: Gene transfer and oncolytic viruses provide new therapeutic approaches for the treatment of hematologic malignancies. However, it is still too early to introduce gene delivery or oncolytic viruses into standard clinical protocol. It is very important to discuss the obstacles that gene transfer and oncolytic virotherapy face for the further clinical application for the treatment of hematologic malignancies, and updating the advances made to overcome them. The major concerns in this review include the approaches of the development of immuno-stimulatory gene transfer mediated-vaccination for leukemia therapy, RNAi-based therapy for leukemia and enhancement of sensitivity of target malignant cells to virotherapy and alteration of host immune response to favor oncolytic viruses. We conclude with a perspective on the future of the gene therapy and virotherapy for the treatment of hematologic malignancies, emphasizing the problems we should solve and the technological requirements for further clinical applications.
Export Options
About this article
Cite this article as:
Jiang Yingzhe, Xia Bing, Zhang Yizhuo*, Xu Wen, Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles, Current Gene Therapy 2016; 16 (6) . https://dx.doi.org/10.2174/1566523217666170215154755
DOI https://dx.doi.org/10.2174/1566523217666170215154755 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Teaching Pharmacogenetics in Low and Middle-Income Countries: Team Based Learning and Lessons Learned at the American University of Beirut
Current Pharmacogenomics and Personalized Medicine A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia
Current Topics in Medicinal Chemistry Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy
Current Cancer Drug Targets Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
Current Cancer Drug Targets Wnt Signaling and Prostate Cancer
Current Drug Targets Could Resveratrol be a Useful Drug for the Treatment of Malignant Hemopathies?
Recent Patents on Anti-Cancer Drug Discovery Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives
Current Medicinal Chemistry Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Induction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design Immunological Aspects of Adult T-Cell Leukemia/Lymphoma (ATLL), a Possible Neoplasm of Regulatory T-Cells
Current Immunology Reviews (Discontinued) Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis
Current Pharmaceutical Design Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Etanercept for the Treatment of Dermatological Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Discovery of Modulators of Protein-Protein Interactions: Current Approaches and Limitations
Current Topics in Medicinal Chemistry New Therapies for Patients with Chronic Lymphocytic Leukemia
Current Cancer Therapy Reviews Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?
Current Cancer Drug Targets